Objective: The goal of the OSCAR programme is to evaluate the performances of genotypic HIV-1 tropism testing in clinical practice using the enhanced sensitivity version of Trafile (ESTA) as reference-assay. Methods: HIV-1 coreceptor-usage was assessed using plasma samples from 406 HIV-1 infected patients by ESTA and by gp120 V3 population-sequencing followed by Geno2pheno (set at a False Positive Rate [FPR] of 10% and 5%). Results: ESTA was successful in 365 (89.9%) samples indicating R5 in 254 (69.6%), and DM/X4 in 111 (30.4% of samples (104 [28.5%] DM and 7 [1.9%] X4). Genotypic-testing successfully assessed viral tropism for all 406 samples, including the 41 with undetermined result by ESTA. Genotypic-tropism testing at a FPR of 5% and 10% was 81.1% and 78.4% concordant with ESTA, respectively. Despite a sensitivity of 48.7% and 55.9% at a FPR of 5% and 10%, respectively, a high concordance (specificity: 95.3% for FPR of 5% and 88.2% for FPR of 10%) between genotypic-tropism testing and ESTA was reached in the detection of R5-tropic viruses. Conclusion: Our results are in line with other European studies, and support the routine use of genotypic tropism testing in clinical-settings for monitoring of HIV-1 infected patients candidate to or failing CCR5-antagonists.
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: Results from the OSCAR Study Group / V., Svicher; R., D'Arrigo; C., Alteri; M., Andreoni; G., Angarano; A., Antinori; Antonelli, Guido; P., Bagnarelli; F., Baldanti; A., Bertoli; M., Borderi; E., Boeri; I., Bonn; B., Bruzzone; A. P., Callegaro; R., Cammarota; F., Canducci; F., Ceccherini Silberstein; M., Clementi; A. D., Monforte; A., De Luca; A., Di Biagio; S., Di Gianbenedetto; G., Di Perri; M., Di Pietro; L., Fabeni; G., Fadda; M., Galli; W., Gennari; V., Ghisetti; A., Giacometti; A., Gori; F., Leoncini; F., Maggiolo; R., Maserati; F., Mazzotta; V., Micheli; G., Meini; L., Monno; C., Mussini; S., Nozza; S., Paolucci; S., Parisi; M., Pecorari; D., Pizzi; T., Quirino; M. C., Re; G., Rizzardini; R., Santangelo; A., Soria; F., Stazi; G., Sterrantino; Turriziani, Ombretta; C., Viscoli; Vullo, Vincenzo; A., Lazzarin; C. F., Perno; Oscar Study, Group. - In: NEW MICROBIOLOGICA. - ISSN 1121-7138. - STAMPA. - 33:3(2010), pp. 195-206.
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: Results from the OSCAR Study Group
ANTONELLI, Guido;TURRIZIANI, Ombretta;VULLO, Vincenzo;
2010
Abstract
Objective: The goal of the OSCAR programme is to evaluate the performances of genotypic HIV-1 tropism testing in clinical practice using the enhanced sensitivity version of Trafile (ESTA) as reference-assay. Methods: HIV-1 coreceptor-usage was assessed using plasma samples from 406 HIV-1 infected patients by ESTA and by gp120 V3 population-sequencing followed by Geno2pheno (set at a False Positive Rate [FPR] of 10% and 5%). Results: ESTA was successful in 365 (89.9%) samples indicating R5 in 254 (69.6%), and DM/X4 in 111 (30.4% of samples (104 [28.5%] DM and 7 [1.9%] X4). Genotypic-testing successfully assessed viral tropism for all 406 samples, including the 41 with undetermined result by ESTA. Genotypic-tropism testing at a FPR of 5% and 10% was 81.1% and 78.4% concordant with ESTA, respectively. Despite a sensitivity of 48.7% and 55.9% at a FPR of 5% and 10%, respectively, a high concordance (specificity: 95.3% for FPR of 5% and 88.2% for FPR of 10%) between genotypic-tropism testing and ESTA was reached in the detection of R5-tropic viruses. Conclusion: Our results are in line with other European studies, and support the routine use of genotypic tropism testing in clinical-settings for monitoring of HIV-1 infected patients candidate to or failing CCR5-antagonists.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
